Abstract-The cold adapted, temperature sensitive and attenuated influenza master donor viruses A/Lenin grad/134/17/57 (H2N2) and B/USSR/60/69 were used to generate vaccine viruses to be included in live attenuated influenza vaccine. These vaccine viruses typically are 6 : 2 reassortant viruses containing the gene segments of the surface antigens haemagglutinin and neuraminidase of current wild type influenza A and influenza B viruses with the gene segments encoding the internal viral proteins, conferring the cold adapted, temperature sensitive and attenuated phenotype, being inherited from the master donor viruses. The 6 : 2 reassortant viruses are selected from co infections between master donor virus and wild type viruses that the oretically may yield as many as 256 combinations of gene segments and thus 256 genetically different viruses. As the time to generate and isolate vaccine viruses is limited and because only 6 : 2 reassortant viruses are allowed as vaccine viruses, sboth selection and creening needs to be both rapid and unambiguous. The screen ing of reassortant viruses by RT PCRs using master donor virus and wild type virus specific primer sets is described to select both influenza A and influenza B 6 : 2 reassortant viruses to be used in seasonal and pan demic live attenuated vaccine, unambigously.
Live attenuated influenza vaccine (LAIV) is in use in Russia for decades and since 2003 in the United
States of America. The Russian LAIV is based on the master donor viruses (MDVs) A/Leningrad/ 134/17/57 (H2N2) and B/USSR/60/69 which are cold adapted, temperature sensitive and attenuated [1, 6, 8] . LAIV has a long record of being safe and effi cacious. The safety of LAIV is guaranteed by its cold adapted, temperature sensitive and attenuated pheno type which limits viral replication to the upper respira tory tract where the vaccine is administered. Efficacy is achieved by induction of local and systemic humoral and cellular immune responses accomplished by mim icking natural infection.
The segmented nature of the influenza virus genome enables exchange of each of eight gene seg ments between two viruses following dual infection. This process is referred to as reassortment and the resulting viruses are called reassortant viruses. Reas sortment is exploited in generating attenuated vaccine viruses to be used in LAIV. Circulating wild type influ enza A or B virus recommended by WHO for use in 1 The article was translated by the authors. current epidemic season as vaccine candidates are co infected with MDVs. The sole one of interest is a so called 6 : 2 reassortant virus which contains the gene segments encoding the surface glycoproteinshaemagglutinin (HA) and neuraminidase (NA)-of the wild type virus to be represented in the vaccine while the remaining gene segments, which encode the internal viral proteins, including those conferring attenuation, must originate from the MDV. co-infection, antiserum raised against the MDV and low temperature of incubation are being used in subse quent selective passages. Since time to generate vac cine viruses is limited and only 6 : 2 reassortant viruses are acceptable for inclusion in LAIV, a rapid, unam biguous and reliable method to screen reassortant viruses is of utmost importance.
Here, we describe RT PCR methods using gene segment and virus (sub)type specific primers allowing for rapid and unequivocal screening of reassortant influenza A and influenza B viruses to be used in sea sonal and pandemic LAIV.
MATERIALS AND METHODS
Viruses. Influenza wild type viruses were obtained from CDC (Atlanta, GA) and from the National Insti tute for Biological Standards and Control (NIBSC, Potters Bar, UK). The MDVs A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 were obtained from the Institute of Experimental Medicine (Saint Petersburg, Russia). Viruses were propagated in 10 to 11 day old embryonated hen's eggs. Reassortant viruses were gen erated by routine technique in embryonated chicken eggs or Madin-Darby Canine Kidney (MDCK) cells (ATCC, Cat. No. CCL 34) as described in [18] . Briefly, equal doses of MDV and wild type virus were inoculated into eggs or cells and incubated at optimum temperature of 32°C (co infection). The development of vaccine reassortants involved sequential passages of reassortant progeny at 25°C in the presence of antise rum to MDV and by limit dilution cloning in the pres ence of antiserum to MDV. RNA isolation. RNA was isolated from influenza virus infected allantoic fluid or cell culture superna tant using the QIAamp Viral RNA Minikit according to the manufacturer's instructions (Qiagen GmbH, Hilden, Germany). cDNA synthesis. cDNAs were synthesized using commercially available Quantitect Reverse Transcrip tion Kit according to the manufacturer's instructions (Qiagen GmbH, Hilden, Germany). For cDNA syn thesis universal primers were used so that in a single reaction cDNAs were generated for all eight gene seg ments. These cDNAs were used as templates in the PCRs. The universal forward primer (Invitrogen) used for influenza A viruses was AUNIVERSALF (5'TCGA CGTCTCAGGGAGCAAAAGCAGG). The univer sal forward primer (Invitrogen) used for influenza B viruses was BUNIVERSALF (5'ACGTTGCAAGCA GAAGC). The thermal cycler program for the reverse transcription (RT) reaction was as follows: 42°C for 2 min: (put on ice while adding next step): 42°C for 15 min: 95°C for 3 min.
Design of PCR programs and selection of primers for screening of reassortant influenza A and B viruses. PCR programs and primers were designed such that clear PCR products were obtained for the gene seg ments of one of the parental viruses used in co infec tion (MDV or wild type virus) while under the same PCR conditions and using the same primers no PCR products were obtained for the other parental virus. Gene segment and virus (sub)type specific primers were selected in such a way that PCR products of dif ferent sizes are obtained for wild type virus and MDV specific primers and that wild type virus specific prim ers do not amplify MDV gene segments and vice versa. Twelve PCR programs that were used for genotyping of reassortant viruses in order to select 6 : 2 vaccine viruses are presented in Table 1 RNA was a popular assay in the 1980s [10, 11, 13, 15] . However, this technique is laborious and time consum ing. With respect to polyacrylamide gel electrophoresis, migration patterns of RNAs derived for MDV and wild type virus may be difficult to distinguish.
An alternative approach is the use of multiplex RT PCRs that yield a yes/no result [4, 5, 9] . This method is currently in use both for typing of influenza A and B viruses, subtyping of influenza A virus and for screen ing of reassortant live influenza vaccine virus strains. In brief, primers are selected that specifically amplify the genes encoding the internal proteins of the MDV and the surface glycoproteins HA and NA of the wild type virus. By optimizing the primers and PCR condi tions, multiple primer sets can be mixed and more than one PCR reaction can be run in a single tube. The authors were able to determine the origin of all eight gene segments of reassortants in a total of three PCR reactions which allows for screening of numerous viruses in a relatively short period of time. However, using the multiplex PCRs no answer can be given about cleanliness of the reassortant virus. It cannot be ruled out that the reassortant virus is contaminated with another reassortant virus containing one or more wild type virus gene segments as these are not detected in their PCRs. The multiplex PCR definitely is attrac tive for initial screening, but needs additional PCRs or sequencing to rule out contamination with other reas ssortant viruses containing wild type gene segments.
One of the most reliable method is RT PCR fol lowed by digestion of PCR products with restriction enzymes (Restriction Fragment Length Polymor phism or RFLP) [2, 3, 7, 12, 14, 17] . RFLPs reveal differences in sequences of RNA segments as well as by different lengths of the restriction fragments pro duced by enzymatic digestion of a selected region of gene. Digested products are detected by ethidium bro mide staining after agarose gel electrophoresis. With respect to RFLP, the use of restriction enzymes has several specific disadvantages, for instance, restriction enzymes may not always fully cut a PCR product, which complicates the determination of the origin of gene segments of reassortants. Incomplete digestion may result from insufficient enzyme activity or could indicate that the virus is not clean. The aim of this study was to design a PCR method using gene segment and virus (sub) type specific prim ers allowing for rapid and unequivocal screening of reassortant influenza A and influenza B viruses to be used in seasonal and pandemic LAIV.
Seasonal influenza A (H1N1 and H3N2) virus spe cific primers. Virus subtype specific primer sets were designed for each of the gene segments of wild type seasonal influenza A H1N1 virus and the A/Lenin grad/134/17/57 (H2N2) MDV (Tables 2, 3 ). H1N1 or H3N2 specific primers only yielded PCR products for gene segments derived from H1N1 or H3N2 virus respectively, while MDV specific primers only yielded PCR products for MDV derived gene segments. More over, the PCR product obtained with wild type virus specific primers differed in size from the PCR product obtained with MDV specific primers. Thus, the yes/no result and the difference in size make it easy to dis criminate the PCR products on gel and to determine the origin of each of the gene segments in a reassortant virus.
An example is shown in Fig. 1 . As can be seen in this figure, reassortant possessed HA and NA from A/Brisbane/10/2007 (H3N2) wild type virus, which was in use for vaccine production in the 2009-2010 influenza season. Vaccine candidate virus yielded PCR products for HA (Fig. 1d) and NA (Fig. 1f) H3N2 specific primers but not when MDV specific primers were used). Contrary, the reassortant H3N2 virus yielded PCR products using MDV specific prim ers for PB2 (Figure 1a) , PB1 (Fig. 1b) , PA (Fig. 1c) , NP (Fig. 1e) , M (Fig. 1g) and NS (Fig. 1h ) gene seg ments but no PCR products were obtained using H3N2 specific primers, clearly demonstrating that the six gene segments encoding the internal viral proteins all originated from MDV. Mixed RT PCR. For the determination of the ori gin of the HA and NA encoding gene segments, so called mixed PCRs were developed whereby in a single reaction MDV and wild type seasonal influenza A (H1N1 or H3N2) specific primers were used. The primers were selected in different regions of the gene segments resulting in different sizes of PCR products obtained for MDV and wild type virus.
An example is shown in Fig. 2 . As can be seen in the left panel (Fig. 2a) , H1N1 virus yields a PCR product with H1 specific primers and a mixture of PCR prod uct with H1 and H2 (MDV) specific primers, but not with H2 or H3 specific primers alone. Contrary, MDV yields a PCR product using H2 specific primers and a mixture with H1 and H2 specific primers, but not with H1 specific primers alone. Since the size of the PCR product obtained with the H1 specific primers differs from that obtained with H2 specific primers, the mixed H1/H2 PCR can be used to easily determine the virus subtype in a single PCR reaction. In case of a mixture of two different subtypes, two clearly sepa rated PCR products are obtained in this mixed PCR. Thus, in the event that the serum used during selective passages following co infection is not completely blocking viruses containing the haemagglutinin of MDV, this will be clearly visible in the mix PCR. Anal ogous to the H1/H2 mixed PCR, a H3/H2 mixed PCR was developed to distinguish wild type and reassortant H3 viruses from H2 viruses (right panel, Fig. 2b) .
In addition to the mixed PCR for determination of the origin of HA, a mixed PCR was developed to dis tinguish neuraminidase N1 from N2. As can be seen in Fig. 3 , A/Brisbane/59/2007 (H1N1) virus, yields a PCR product with N1 specific primers or a mixture with N1 and N2 specific primers but not with N2 (MDV) specific primers. The opposite is found for MDV. As with the H1/H2 mixed PCR, a mixture of two viruses will easily be detected as two bands of dif ferent size will appear in gel electrophoresis. segment of both the MDV and the wild type parental viruses, PCR products of different sizes were obtained with MDV and wild type virus specific primer sets, respectively. Using the primers the other way around (MDV with wild type virus specific primers and wild type virus with MDV specific primers) no PCR prod ucts were obtained. When reassortant viruses are ana lyzed in this way, the genome composition will imme diately be clear and, importantly, will demonstrate whether or not the virus is of a single genotype. In case of a mixture of two or more genetically different viruses this will become clear by the appearance of two different sized PCR products for one or more gene segments. This demonstrates that the mixed PCR assay is very specific and may also be used for typing of influenza A and B isolates from influenza patients and from individuals vaccinated with LAIV. Seasonal influenza B virus specific primers. Regions of naturally occurring sequence diversity between cur rently circulating wild type influenza B viruses and the B/USSR/60/69 MDV were identified to design gene segment specific primer sets analogous to wild type influenza A viruses and A/Leningrad/134/17/57 (H2N2) MDV (Table 4) .
Pandemic and prepandemic influenza A (H1N1 and H5N1) virus specific primers. In 2009, a novel H1N1 virus appeared that rapidly spread around the globe resulting in the first influenza pandemic of 21 st cen tury. This H1N1 virus (of which A/California/07/09 (H1N1) is an example) is quite different from the H1N1 virus that circulated previously. Therefore, new primers were designed that allowed for discrimination of gene segments of this novel H1N1 virus from those of MDV (Table 5) .
Today both circulating H1N1 California like influ enza viruses of swine origin and highly pathogenic A (H5N1) avian influenza viruses still confer a potential influenza pandemic risk. The use of highly pathogenic influenza viruses with pandemic potential in the gen eration of vaccine viruses to be used in LAIV is undes ired from an operator safety point of view. In these cases alternatives are to be sought for donation of the proper surface glycoproteins of A (H5N1) avian influ enza virus in an MDV backbone. The use of reassor tant viruses based on A/PR/8/34 (H1N1) could be an alternative to wild type virus. A/PR/8/34 (H1N1) is routinely used for generating high yield reassortant influenza A viruses for inactivated influenza vaccines including H5N1. In this case, the HA of the H5N1 virus was first modified by removal of the multibasic cleavage site to make haemagglutinin apathogenic. Than modified HA together with NA were put in a background of A/PR/8/34 (H1N1) using reverse genetics [16] . These H5N1-PR8 based reassortant viruses produced by NIBSC (UK) and CDC (USA) could well be used in co infections with cold adapted MDV to generate new reassortant viruses. Replace ment of PR8 internal genes in the genome of H5N1-PR8 based reassortants with appropriate genes of MDV will lead to the generation of a prepandemic LAIV candidate. Also for these situations, primers were designed that enabled discrimination between six internal gene segments derived from MDV or A/PR/8/34 (H1N1) virus, and HA and NA derived from MDV and H5N1 virus, respectively (Table 6 ).
In conclusion, RT PCRs were developed that unambiguously demonstrate the genome composition of A and B reassortant influenza viruses. These RT PCRs allow for the clear and rapid selection of both influenza A and influenza B vaccine viruses (6 : 2 reas sortant viruses) to be used in LAIV production.
